| Popis: |
COVID-19 infect the respiratory tract, can be a predisposing factor for bacterial co-infection, which is can affect the severity to death. The antibiotics are given empirically, which is Azithromycin is often used for pneumonia indications. Azithromycin is macrolide antibiotic, effective against bacteria by inhibiting bacterial protein synthesis. Clinical characteristics and severity of COVID-19 can be an indication of taking Azithromycin. This research is aimed to describe the clinical characteristic and severity in the patients of COVID-19 taking Azithromycin. The research uses descriptive method with cross sectional approach. It uses the medical record of patients with confirmed COVID-19 hospitalized at the Al-Ihsan Hospital for the period August 2020 - March 2021. The sampling technique used was purposive sampling from medical record data with a total sample of 88 people who entered the inclusive criteria. The results of this research found that from the total of 88 subjects. Patients aged 18-60 years dominate 67 people (>75%) in Azithromycin groups. 46 people (52.27%) are severe COVID-19 (SpO2 ≤ 90%). Conclusion: The use of Azithromycin dominated age 18-60 years, had a comorbid condition and were used in patients with severe COVID-19 and non-severe COVID-19. Abstrak. Infeksi COVID-19 di saluran pernapasan dikatakan dapat menjadi faktor predisposisi dari ko-infeksi bakteri yang dapat berakibat buruk terhadap derajat keparahan hingga kematian. Pemberian antibiotik pada pasien COVID-19 secara empirik sering menggunakan obat dengan indikasi pneumonia seperti Azitromisin. Azitromisin adalah antibiotik golongan makrolida yang menghambat sintesis protein bakteri. Karakteristik klinis dan derajat penyakit dapat menjadi indikasi pemberian azitromisin. Tujuan penelitian ini adalah untuk mengetahui gambaran karakteristik klinis dan derajat keparahan pasien COVID-19 yang diberikan Azitromisin di RSUD Al-Ihsan, Bandung. Penelitian deskriptif ini menggunakan pendekatan cross sectional dan menggunakan data rekam medis pasien terkonfirmasi COVID-19 rawat inap di RSUD Al-Ihsan periode Agustus 2020 – Maret 2021. Sampel dilakukan dengan teknik purposive sampling. Total subjek penelitian 88 orang yang termasuk kriteria inklusi. Hasil penelitian menggambarkan pasien yang mendapatkan Azitromisin ini sebanyak 67 orang (76.13%) berusia 18-60 tahun dan 53 orang (48.76%) memiliki komorbid. Sebanyak 46 orang (52.27%) penerima Azitromisin memiliki COVID-19 derajat berat (SpO2 ≤ 90%). Kesimpulan: Pemberian Azitromisin didominasi karakteristik usia 18-60 tahun, dan memiliki komorbid. Terapi Azitromisin diberikan pada pasien dengan derajat COVID-19 tidak berat dan berat. |
